Discontinuation of the development of　"Remogliflozin" by GlaxoSmithKline

Kissei Pharmaceutical Co., Ltd. (President & CEO: Mutsuo Kanzawa) announced that GlaxoSmithKline (headquartered in the UK) decided to discontinue the development of the novel agent for diabetes, "remogliflozin (generic name)" (Kissei's development code: KGT-1681), as a result of evaluating circumstances including the development status of SGLT2 inhibitors by competitors.

　Kissei discovered the SGLT2 inhibitor, "remogliflozin", and the SGLT1 inhibitor, "KGA-3235 (Kissei's development code)", for diabetes and licensed the development and marketing right of the agents in the US, Europe, etc. to GlaxoSmithKline. Remogliflozin is in the stage of phase II clinical studies and KGA-3235 is in the stage of phase I clinical study.

　With regard to the development of SGLT inhibitors, while GlaxoSmithKline decided to discontinue the development of remogliflozin, it will continue to develop KGA-3235.

＜Reference＞
Sodium-dependent Glucose Transporter 1 (SGLT1):
One of the glucose transporters involved with the transport of glucose in vivo. It is found in large amounts inside the small intestine, and plays a major role in glucose absorption inside the intestinal tract. SGLT1 inhibitors suppress glucose absorption in the intestinal tract by directly inhibiting the actions of SGLT1.


Sodium-dependent Glucose Transporter 2 (SGLT2):
One of the glucose transporters involved in the transport of glucose in vivo. It exists specifically inside the kidneys and plays a major role in the glucose reabsorption process inside the kidneys. Although blood glucose is filtered by the kidneys and migrates to the urine, SGLT2 returns glucose back to the blood stream.